We are live on ! Find out more
GRI

GRI Bio

4 hedge funds and large institutions have $140K invested in GRI Bio in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% more ownership

Funds ownership: 0%0.03% (+0.03%)

20% less funds holding

Funds holding: 54 (-1)

21% less capital invested

Capital invested by funds: $177K → $140K (-$37.5K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.06%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$96.4K +$250K +105 New
UBS Group
2
UBS Group
Switzerland
$34.5K +$88.1K +37 +3,700%
BlackRock
3
BlackRock
New York
$8.25K +$21.4K +9 New
TRCT
4
Tower Research Capital (TRC)
New York
$591
Bank of America
5
Bank of America
North Carolina
$4
ACM
6
Altium Capital Management
New York
-$143K -30 Closed
HF
7
HRT Financial
New York
-$14K -3 Closed
TSS
8
Two Sigma Securities
New York
-$9.65K -2 Closed
Wells Fargo
9
Wells Fargo
California
-$3

GRI Hedge Fund Activity: Q2 2024 in Review

4 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q2 2024, worth a combined $140K — down 21% from $177K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of GRI and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $250K. The largest seller was Altium Capital Management, exiting entirely with an estimated $143K sold.

  • 4 institutional investors held GRI Bio (GRI) as of Q2 2024, down from 5 in Q1 2024.
  • Funds reported $140K of GRI Bio stock for Q2 2024, down 21% quarter-over-quarter.
  • 2 funds opened new GRI Bio positions in Q2 2024 and 3 closed out, a net change of -1 holder.
  • The largest GRI Bio buyer in Q2 2024 was Armistice Capital, an estimated $250K added.
  • The largest GRI Bio seller in Q2 2024 was Altium Capital Management, an estimated $143K sold.

Based on aggregated 13F filings for Q2 2024.